Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa study of aAVC-WT1 in MRD-positive acute myeloid leukemia or high-risk myelodysplastic syndrome
jRCT2033200305Phase 2Completed
- Start
- Nov 2021
- Modality
- Vaccines & Immunotherapeutics, Cell Therapies, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of aAVC-WT1 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Primary endpoints: Safety and Safety-related examinations. Started Nov 2021; status: completed.
02
Drugs
aAVC-WT1
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on jRCT2033200305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2033200305.